Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: The median duration of survival for the group treated with FOLFOX4 and bevacizumab was 12.9 months compared with 10.8 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for death = 0.75; P = .0011), and 10.2 months for those treated with bevacizumab alone. The median progression-free survival for the group treated with FOLFOX4 in combination with bevacizumab was 7.3 months, compared with 4.7 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for progression = 0.61; P < .0001), and 2.7 months for those treated with bevacizumab alone. The corresponding overall response rates were 22.7%, 8.6%, and 3.3%, respectively (P < .0001 for FOLFOX4 with bevacizumab v FOLFOX4 comparison). Bevacizumab was associated with hypertension, bleeding, and vomiting. CONCLUSION:
|
Authors | Bruce J Giantonio, Paul J Catalano, Neal J Meropol, Peter J O'Dwyer, Edith P Mitchell, Steven R Alberts, Michael A Schwartz, Al B Benson 3rd |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 41
Issue 21
Pg. 3670-3675
(Jul 20 2023)
ISSN: 1527-7755 [Electronic] United States |
PMID | 37459754
(Publication Type: Corrected and Republished Article)
|